The NHMRC e-ASIA 2022 Joint Research Program will support Australian participation and collaboration in leading international collaborative research through the e-ASIA Joint Research Program (e-ASIA JRP). The e-ASIA JRP supports international joint research projects in the East Asia region on a multilateral basis, and promotes the interaction of researchers through scientific workshops.
The e-ASIA JRP selects research projects through an open call for proposals. Fields of cooperation are decided among the e-ASIA participating member organisations and funding is for up to three years.
NHMRC has committed up to $3 million for up to 4 grants with a capped maximum value of $750,000 per grant to support the Australian component of successful projects in the e-ASIA JRP 11th Health Research call. Applications are invited for projects commencing in 2023 addressing the following research topics in the e-ASIA JRP Health research 11th joint call:
- Infectious diseases (including antimicrobial resistance)
Participating Member Organisations in this call are:
- Australia: National Health and Medical Research Council (NHMRC)
- Japan: Japan Agency for Medical Research and Development (AMED)
- Philippines: Department of Science and Technology (DOST-PCHRD)
- Thailand: National Science and Technology Development Agency (NSTDA)
- Thailand: Program Management Unit for Human Resources and Institutional Development, Research and Innovation (PMU-B)
- United States of America: National Cancer Institute (NCI)
- United States of America: National Institute of Allergy and Infectious Diseases (NIAID)
- NHMRC will advertise this call through GrantConnect, Tracker, RAO Alert and on the NHMRC website.
- NHMRC opens the grant opportunity in NHMRC's Sapphire grants management system for researchers to participate in the call:
- The Lead Principal Investigator of the collaborative project is required to submit the Common Application to the e-ASIA Program Secretariat by the specified due date of 30 March 2022. For more details please visit the e-ASIA website.
- Applicants from the Australian team must submit an application addressing the criteria outlined in the Grant Opportunity Guidelines to NHMRC for assessment by the nominated due date.
- Collaborating partners are responsible for submitting completed applications to respective member organisations supporting the topic call in line with their application closing dates. Note: Collaborating Partners should confirm their Member Organisation is participating in the research call topic prior to submitting an application.
- NHMRC conducts eligibility checks for Australian collaborations.
- NHMRC conducts peer review of applications submitted.
- NHMRC submits short listed eligible applications to the e-ASIA Joint Review Meeting (membership comprises representatives from each of the participating member organisations).
- e-ASIA Joint Review meeting compiles a final joint ranking list and recommendations for funding to be presented to the e-ASIA Board for approval.
- NHMRC funding recommendations approval process.
The e-ASIA JRP has specific eligibility criteria for applicants. Applications will be excluded from consideration if eligibility requirements are not met, including:
- A minimum of three collaborating partners from supporting member organisations participating in a call topic, per application.
- Applications specific to each participating member organisation must be completed by the Chief Investigator A (CIA) in their country (e.g. Australian CIA submits to NHMRC while the Japanese CIA submits to the Japan Agency for Medical Research and Development (AMED). More detailed eligibility requirements can be found in the e-ASIA 11th Health Research common call guidelines available on the e-ASIA website.
- For details regarding the NHMRC e-ASIA 2022 JRP peer review process, please refer to the NHMRC e-ASIA 2022 JRP Peer Review Guidelines available from the download section below.
Grant at a glance
- NHMRC no longer provides ‘in-kind’ as a mechanism for support.
- NHMRC requires that collaborations must include a lead PrincipaI Investigator (PI) (refer to section 4.1) or PI from at least one of the participating member organisations from the following countries: